November 14, 2024CorporateTerumo Blood and Cell Technologies Unlocks New Chapter of Localization in China to Facilitate Blood and Cell Treatment Options for Patients
November 12, 2024CorporateTerumo Blood and Cell Technologies Merges Therapeutics Units to Enhance Patient Care Across Treatment JourneyNew Global Therapy Innovations business unit, led by Veerle d’Haenens, aims to unify therapeutic apheresis and cell and gene therapy expertise to expand therapeutic possibilities
November 07, 2024FinancialNotice Concerning Revisions to Full-Year Consolidated Financial Guidance for Fiscal Year Ending March 31, 2025 (FY2024) (PDF 85.27 KB)
Top Management Message Message from top management to shareholders and investors. /investors/management/message Corporate Governance /about/governance Compliance /about/compliance Leadership Team /about/leadership Business Risks Major risks that may affect the business performance and financial position of the Terumo Group are described. /investors/management/risk IR Policy /investors/management/ir_policy Disclaimer /investors/disclaimer
